曼恩凯德制药

最新新闻

• 评级变动
  Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Bruker (BRKR) and BrightSpring Health Services, Inc. (BTSG)
  TipRanks · 2026/7/27
• H.C. Wainwright Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  A Quick Look at Today's Ratings for MannKind(MNKD.US), With a Forecast Between $4.75 to $10
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 公司公告
  MannKind | 4: Statement of changes in beneficial ownership of securities-Director Binder Steven B.
  SEC · 2026/9/29
• Truist Financial Maintains MannKind(MNKD.US) With Buy Rating, Announces Target Price $6
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Wells Fargo Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 公司公告
  MannKind | 4: Statement of changes in beneficial ownership of securities-Director Binder Steven B.
  SEC · 2026/5/14
• 公司公告
  MannKind | 4: Statement of changes in beneficial ownership of securities-Director Binder Steven B.
  SEC · 2026/5/23
• 评级变动
  Cantor Fitzgerald Maintains MannKind(MNKD.US) With Buy Rating, Cuts Target Price to $8
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Wedbush Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• H.C. Wainwright Keeps Their Buy Rating on MannKind (MNKD)
  TipRanks · 2026/9/22
• 评级变动
  Wells Fargo Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• Truist Financial Maintains MannKind(MNKD.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 公司公告
  MannKind | 4: Statement of changes in beneficial ownership of securities-Director Binder Steven B.
  SEC · 2026/9/15
• 公司公告
  4: MannKind | 4: Statement of changes in beneficial ownership of securities-Director Binder Steven B.
  SEC · 2026/7/18
• 评级变动
  A Quick Look at Today's Ratings for MannKind(MNKD.US), With a Forecast Between $4.75 to $13
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Wells Fargo Maintains MannKind(MNKD.US) With Buy Rating, Raises Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/7/30
• 评级变动
  RBC Capital Maintains MannKind(MNKD.US) With Hold Rating, Maintains Target Price $4.75
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)
  TipRanks · 2026/5/28
• Cantor Fitzgerald Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/9/11

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。